Home › Funds › Vivo Capital, LLC › SABS
Vivo Capital, LLC position in SABS
SAB Biotherapeutics Inc · Health Care
Vivo Capital, LLC reported holding 6,915,011 shares of SABS (SAB Biotherapeutics Inc) in its Q3 2026 13F filing — a position valued at US$21.9M, representing 2.49% of its reported portfolio and ranking #16 among its reported holdings. Vivo Capital, LLC has disclosed SABS holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Vivo Capital, LLC's SABS position evolved
Vivo Capital, LLC first disclosed a stake in SABS in Q3 2025 at 11,420,000 shares (US$23.0M). The position peaked in Q1 2026 at 11,420,000 shares, worth US$43.7M. Across 5 filings, Vivo Capital, LLC increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 6,915,011 shares valued at US$21.9M — a reduction of -384,898 shares quarter over quarter.. Notable position changes include a 36% trim in Q2 2026 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 11.42M | $22.95M | New |
| Q4 2025 | 11.42M | $42.71M | Hold |
| Q1 2026 | 11.42M | $43.74M | Hold |
| Q2 2026 | 7.30M | $28.47M | Reduce |
| Q3 2026 | 6.92M | $21.92M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SABS and 13F data
SABS (SAB Biotherapeutics Inc) is a Health Care company. 71 other funds we track also report a position in SABS — the largest reported positions include Caligan Partners LP (US$31.1M), Commodore Capital LP (US$11.2M), Spruce Street Capital LP (US$8.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SABS
- Caligan Partners LP 7.97M sh · $31.07M · Q2 2026
- Commodore Capital LP 2.87M sh · $11.19M · Q2 2026
- Spruce Street Capital LP 2.20M sh · $8.57M · Q2 2026
- Sessa Capital IM, L.P. 2.20M sh · $8.57M · Q2 2026
- Sanofi 2.20M sh · $6.97M · Q3 2026
- Propel Bio Management, LLC 1.19M sh · $3.76M · Q3 2026
- Seven Fleet Capital Management LP 736.08K sh · $2.87M · Q2 2026
More on Vivo Capital, LLC
FAQ
How long has Vivo Capital, LLC held SABS?
Vivo Capital, LLC has disclosed SABS holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Vivo Capital, LLC's current position in SABS?
As of Q3 2026, Vivo Capital, LLC holds 6.92M shares of SABS (SAB Biotherapeutics Inc), valued at $21.92M, representing 2.49% of its reported portfolio and ranking #16.
Has Vivo Capital, LLC been buying or selling SABS?
In the latest 13F filing (Q3 2026), Vivo Capital, LLC reduced its position in SABS. The position peaked in Q1 2026 at 11.42M shares.
Which other funds hold SABS?
Other major institutional holders of SABS include Caligan Partners LP, Commodore Capital LP, Spruce Street Capital LP, among 71 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.